October 9, 2021 The National Cancer Institute awards a $2.4 M Fast-Track Phase 1/Phase 2 Small Business Innovation Research grant to LifeGene-Biomarks, Inc. for the project titled: Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America. The objective of this project is to demonstrate the commercialization feasibility of the CervicalMethDx Test, a precision methylation solution for the cervical cancer screening space. We will partner with the ESTAMPA Study (NCT01881659) Consortium to introduce precision epigenetic services to residents of Honduras, Colombia, Argentina and Paraguay.  We will focus on patients with persistent oncogenic Human Papilloma Virus (HPV+) infection and cervical dysplasia, to triage patients into colposcopy and subsequent biopsy or treatment.  Efficient riage into colposcopy will decrease unnecessary treatments, improve health-care quality, decrease health care costs, and reduce cervical cancer mortality among women in Low and Middle Income Countries (LMICs) who have a higher burden of cervical cancer.